Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
424B5 - Chiron Real Estate Inc. (0001533615) (Filer)
424B5 - Chiron Real Estate Inc. (0001533615) (Filer)
8-K - Chiron Real Estate Inc. (0001533615) (Filer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most
–Completes Corporate Rebrand– –Announces 2026 Strategic Objectives & Full Year 2026 Core FFO Guidance– –Announces Change from Quarterly to Monthly Dividends– Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced financial results for the three and twelve months ended December 31, 2025 and other data. Mark Decker, Jr., Chief Executive Officer and President stated, "We're about eight months into the transformation of the business and we are making great progress. I'm grateful for all the hard work that's produced these early results and the support of our Board. We can see the business we want and a path to get there. As this quarter demonstrates, we have a s
Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most